Gene therapy specialist AskBio Inc, a wholly owned and independently operated subsidiary of German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009.
The product is an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease.
With this announcement, the AB-1009 programme progresses to Phase 1/2 and AskBio will commence a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting the first patient in early 2026.
In September 2024, AskBio formed a strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. BBM granted AskBio a sublicence to use the proprietary AAV capsid in the AB-1009 programme and provided AAV vector production services.
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe